Propofol infusion syndrome resuscitation with extracorporeal life support: a case report and review of the literature
© Mayette et al.; licensee Springer. 2013
Received: 28 June 2013
Accepted: 3 September 2013
Published: 23 September 2013
We report a case of propofol infusion syndrome (PRIS) in a young female treated for status epilepticus. In this case, PRIS rapidly evolved to full cardiovascular collapse despite aggressive supportive care in the intensive care unit, as well as prompt discontinuation of the offending agent. She progressed to refractory cardiac arrest requiring emergent initiation of venoarterial extracorporeal membrane oxygenation (ECMO) during cardiopulmonary resuscitation (CPR). She regained a perfusing rhythm after prolonged (>8 hours) asystole, was weaned off ECMO and eventually all life support, and was discharged to home. We also present a review of the available literature on the use of ECMO for PRIS.
KeywordsPropofol infusion syndrome Cardiogenic shock Extracorporeal membrane oxygenation
Propofol infusion, frequently used in the intensive care setting for sedation or for refractory status epilepticus, has been associated with a rare, but grave complication: propofol infusion syndrome (PRIS). We describe a case of particularly severe PRIS that was successfully resuscitated with extracorporeal membrane oxygenation (ECMO), despite prolonged evidence of cardiopulmonary arrest (asystole). This case highlights the potential severity of this syndrome, the benefits of aggressive treatment, which may include extracorporeal circulation, but also the debilitating complications associated with ECMO.
The patient is a 20-year-old Caucasian female with a past medical history significant only for anemia who presented to a referring center’s emergency department (ED) with persistent spinal headache following a normal spontaneous vaginal delivery managed with epidural analgesia. She underwent a blood patch on postpartum day 1, which was repeated on postpartum day 3 without relief of her headache. She returned to the ED postpartum day 5 for continued headaches and was admitted for bed rest and caffeine therapy. On the night of admission, the patient started seizing (tonic-clonic) and became apneic requiring intubation and intensive care unit (ICU) admission. The seizures abated before administration of lorazepam, but she had a second seizure and was placed on a midazolam and propofol infusion for sedation and seizure control. In consultation with neurology, she was started on phenytoin and valproic acid. Ceftriaxone and vancomycin were started empirically for meningitis; both were stopped early, because cultures remained negative. A magnetic resonance imaging (MRI) study of her lumbar spine showed a cerebral spinal fluid (CSF) leak with evidence of CSF anterior and posterior to the thecal sac from the upper lumbar spine extending down to the sacrum. A brain MRI demonstrated signs of intracranial hypotension without evidence of hemorrhage. Magnetic resonance venography (MRV) of the brain was negative for venous thrombosis. Neurosurgery was consulted for possible surgical repair of the CSF leak but determined that the leak could be managed medically with bed rest, Trendelenburg positioning, and a larger blood patch. During the next 12–24 hours, the patient continued to present seizures as demonstrated by spot electroencephalography (EEG). Her propofol infusion was increased to 150 μg/kg/min (9 mg/kg/h) in an attempt to achieve epileptic burst suppression. The following day, the patient rapidly developed fluid resistant shock, a severe metabolic acidosis, acute oliguric kidney failure, an elevated creatine kinase, and transaminases. Propofol was discontinued given the concern for possible PRIS; she was resuscitated with crystalloid and started on an epinephrine drip titrated to 150 ng/kg/min to maintain a mean arterial pressure >65 mmHg. She was then emergently transferred to an academic tertiary referral center for a higher level of care.
During the first 8 hours after transfer, her severe acidosis and acute liver failure remained stable and her lactate level improved, but she became oliguric with mild hyperkalemia (5.1 mmol/L) and hypocalcemia (ionized 0.76 mmol/L). Troponins peaked at 15.5 ng/mL (normal < 0.3 ng/mL) on post-transfer day 1. She was placed on continuous renal replacement therapy (CRRT). Cardiology, neurology, and cardiothoracic surgery were all consulted with early discussions of possibly placing the patient on extracorporeal membrane oxygenation (ECMO) or other mechanical cardiac support as a rescue therapy should she worsen. Propofol having been discontinued before transfer to our facility, she was not placed on any other continuous sedation regimen. She started to awaken and move all extremities upon arrival with intermittent following of commands, and only required intermittent boluses of opioids for adequate sedation. A continuous EEG did not show any ongoing seizure activity. Approximately 8 hours after transfer, the patient suffered an episode of unstable ventricular tachycardia (V-tach) requiring three defibrillation attempts (200 Joules biphasic) without CPR (maintained pulse) resulting in return of a sinus tachycardia with a persistent right bundle branch block (RBBB) and septal lead ST-segment depression (Figure 1C). She was loaded with amiodarone and given aggressive calcium/magnesium replacements. Over the subsequent 6 hours, she continued to have a very irritable myocardium/conduction system resulting in atypical intraventricular conduction delays (IVCDs), progressively widening QRS, atrial flutter/fibrillation, and an accelerated junctional escape rhythm (Figure 1D,E,F).
At approximately 16:30 that evening, 18 hours after transfer, the patient suffered another V-tach episode, this time pulseless, requiring 10 minutes of CPR, 6 (1 mg) doses of epinephrine, defibrillations, and 100 mg of IV lidocaine with return of spontaneous circulation. She remained in an accelerated junctional rhythm/V-tach with a perfusing blood pressure (101/64 mmHg, heart rate 135 beats per minute). Because of her continued circulatory and electrophysiologic instability, the decision was made to place a temporary ventricular assist device (VAD; Impella, Abiomed®) under fluoroscopic guidance in the cardiac catheterization laboratory. As she was being prepared to transfer out of the ICU, she went into ventricular fibrillation (V-fib). Again, resuscitation attempts were continued with continuous CPR, epinephrine, and ventilation. The decision was made to place her emergently onto ECMO while undergoing active advanced cardiac life support (ACLS) resuscitation. She was cannulated at the bedside using a percutaneously placed right internal jugular venous catheter and a left femoral arterial catheter for venous-arterial (V-A) ECMO. During cannulation, the patient’s rhythm degraded into a fine V-fib and she became asystolic. Cardiopulmonary resuscitation was continued and after being loaded with 10,000 units of heparin, the patient was placed on the ECMO circuit while still asystolic and remained with minimal cardiac motion as seen on bedside echocardiography. The time from the start of her V-fib arrest to ECMO initiation was 53 minutes with minimal interruptions in CPR and ongoing boluses of epinephrine, vasopressin, bicarbonate, and calcium chloride. Postcardiac arrest therapeutic hypothermia protocol to 32°C for 24 hours was initiated via the ECMO circuit for neurologic preservation.
Additional file 1: Parasternal long axis transthoracic echo video clip observed during 8 hr period of asystole while on ECMO support. (M4V 438 KB)
In addition to the ongoing efforts to decrease her serum potassium, we also attempted unsuccessfully to chemically pace her heart using isoproterenol, epinephrine, and dopamine infusions. Transvenous pacing also was employed without successful electrical capture of the heart. Because of the continued inability to lower the potassium with CRRT the patient was transitioned to intermittent hemodialysis (iHD). During iHD, her potassium finally responded and dropped to 4.5 mEq/L within 1 hour into the dialysis treatment and she regained a paced rhythm. She regained a rapidly improving pulse pressure on arterial line tracing as well as evidence of aortic valve opening on TTE.
After being on ECMO for 5 days, the patient demonstrated a dramatic recovery of cardiac function by TTE with an LVEF 35-40% and normal RV function, facilitating weaning, and removal from the ECMO circuit [1, 2]. She was successfully decannulated from the ECMO circuit to low-dose vasopressors that were rapidly weaned by day 7. Perfusion to her lower extremities (LE) was compromised during ECMO with hypothermia and high-dose pressors, despite the early use of a reperfusion catheter distal to cannulation site (forward limb). Because of concerns for compartment syndrome in left LE (ECMO arterial cannulation site), she underwent fasciotomies. Unfortunately, she eventually required a left below-the-knee amputation (BKA) and a left ileofemoral bypass surgery. She also underwent a brain MRI which showed left frontal and right occipital ischemic strokes, concerning for embolic events or cerebral hypoperfusion.
Despite her complicated ICU course, she gradually awoke with significant residual weakness and paralysis in the left upper extremity. She eventually recovered normal renal function after 1 month of dialysis requirement (creatinine 0.5 mg/dL on follow-up), as well as normal liver function. Her repeat ECGs showed a sinus rhythm with minimal lateral T-wave abnormalities (Figure 1H and I). Outpatient echocardiogram showed normal LV size, wall thickness and contractility, with estimated EF 60%. She had short-term memory deficits and some depression/anxiety from the events but was cognitively intact. During her prolonged hospitalization, she also suffered from Clostridium difficile colitis and developed diffuse calcified lesions in her lungs that were felt to be secondary to amiodarone toxicity. She was transferred from our hospital to rehabilitation after 84 days of hospitalization.
Propofol (2,6-diisopropylphenol) is a commonly used sedative and hypnotic drug in the ICU, allowing easily titratable continuous sedation [3–5]. It has been FDA approved since 1993 for sedation induction and maintenance in anesthesia and intensive care. Its short half-life allows for frequent neurological assessment. Because of the strong antiepileptic and neuro-protective properties of the drug, it is frequently used for treatment of refractory status epilepticus [6–8]. Neuroprotection is thought to be due to inactivation of gamma-aminobutyric acid (GABA) receptors, blockade of excitatory neurotransmitters, reduction in cerebral oxygen consumption and intracranial pressure .
Although propofol has appealing properties as a first line drug for sedation, its clinical use has been limited because of adverse effects. Significant hypotension, especially in the hemodynamically unstable patient from both peripheral vasodilation and cardiac depression, hinders its use. Hypertriglyceridemia and associated complications also are observed in some patients. The clinical effect and occurrence of side effects of propofol are generally dose- and time-dependent .
A rare complication, propofol infusion syndrome (PRIS), was first described in 1992 , and the name PRIS was first used in 1998 . Initially described in children [11–13] and in traumatic brain injury , it has been increasingly reported in critically ill adults [15, 16], including during treatment for refractory status epilepticus. Propofol infusion syndrome typically presents as severe rhabdomyolysis, acute kidney injury, hyperkalemia, metabolic acidosis, and hepatomegaly. Myocardial injury may occur in severe forms, presenting with various ECG changes, including Brugada-like pattern and coved-type ST-segment elevations, severe arrhythmias, and cardiovascular collapse [17–19]. Occurrence of the syndrome, as well as its severity, appears to be dose-dependent, most cases occurring in patients who received a propofol dose in excess of 5 mg/kg/hr (80 μg/kg/min) for at least 48 hours . However, as in our case, the syndrome has been described with short-term, high doses  and long-term, small doses . Additional well-recognized risk factors for its development include the coadministration of catecholamines or corticosteroids [20, 23].
As this constellation of signs and symptoms remains nonspecific and in the absence of a definitive diagnostic test, PRIS is always a presumed diagnosis and a differential diagnosis must always be kept in mind. This includes septic shock with end-organ hypoperfusion, trauma with crush injuries, ongoing seizures, toxic rhabdomyolysis (cocaine, amphetamines), severe alcohol withdrawal/delirium tremens with cardiovascular collapse, tetanus, or severe hypophosphatemia.
The pathophysiology of PRIS is complex. Propofol infusion syndrome has a higher incidence in critically ill patients compared with healthy patients receiving propofol for routine anesthesia. Hence, critical illness, most notably neurologic injury, might act as a priming factor for propofol (with or without catecholamines and corticosteroids) to trigger PRIS . The end-organ damage may result from an imbalance between energy demand and oxygen utilization. Propofol, by increasing malonylcarnitine, impairs uptake and mitochondrial oxidation of long-chain free fatty acids (FFAs) in myocardial and skeletal muscle, resulting in muscle necrosis . Critically ill patients are particularly dependent on FFAs for energy production, and the generation of FFAs from peripheral lipolysis is catecholamine-driven. Propofol also appears to directly inhibit the respiratory electron transport chain in cardiac mitochondria, inhibiting utilization of freely diffusing medium- and short-chain FFAs . The role of catecholamines in the syndrome may be related to direct muscle damage (contraction band necrosis), as seen in other high-catecholamine states like pheochromocytoma  and stress-induced (Tako-Tsubo) cardiomyopathy [27, 28]. Neurologic injury, frequently present in patients suffering from PRIS, also is known to produce a high-catecholamine state with associated muscle damage . Finally, a genetic predisposition of inappropriate fatty acid oxidation (inborn error) has been hypothesized but remains uncertain [24, 30].
Treatment of PRIS first and foremost relies on rapid recognition of the syndrome and removal of the offending agent. Otherwise, the treatment is mainly supportive by the use of inotropic and vasopressive agents, aggressive electrolyte control, hemodialysis, or hemofiltration. As mentioned above, severe forms of PRIS with cardiac injuries and arrhythmias have been reported, with various arrhythmias including asystole , as in our case. For those severe forms of cardiovascular collapse, mechanical circulatory support, using VADs or ECMO has been reported. Extra corporeal membrane oxygenation, especially VA-ECMO as used in this case, can be deployed to temporarily support end-organ blood flow and oxygen delivery using either central or peripheral cannulation . This remains a high-risk procedure, frequently used in extremis when other treatment modalities have failed, or when the patient is too unstable to be transferred to the catheterization laboratory, as in our case. The risk of complications (mechanical complications of the circuit, hemorrhage from anticoagulation and consumptive coagulopathy, vascular trauma induced by large-bore catheters, local thrombosis with limb ischemia and systemic emboli, sepsis) remains significant despite advances in the technique . We found three case reports of the use of ECMO for severe PRIS, two in pediatric populations and one in a young adult [33–35]. To our knowledge, this is the first case of such prolonged documented asystole with survival, despite significant complications.
Review and conclusions
Overall reported mortality for PRIS, usually associated with the cardiac injury, is as high as 64% . The simultaneous presence of multiple characteristics of the syndrome is associated with increased mortality , highlighting the need for education about PRIS and early recognition and treatment. Repeated case reports of this devastating complication of a common ICU drug calls for increased caution and vigilance when using propofol, especially in patients requiring increasing doses of vasopressors or in cardiac failure as advised by the American College of Critical Care Medicine . Many centers have modified protocols of treatment, including refractory status epilepticus, suggesting propofol should be moved to second or third-line choice when alternatives exist. When used, small doses for short periods of time should be the norm. Frequent monitoring of CK and lactate levels, as well as clinical awareness needs to be encouraged. For severe cases with cardiovascular collapse, strong consideration should be given to early transfer to medical centers with capacities for advanced mechanical circulatory support.
Informed consent was obtained from the patient for the publication of this report and any accompanying images.
Propofol infusion syndrome
Extracorporeal membrane oxygenation
Intensive care unit
Magnetic resonance imaging
Cerebral spinal fluid
Magnetic resonance venography
Arterial blood gas
Peek inspiratory pressure
Positive end-expiratory pressure
Fraction of inspired oxygen
White blood cell
Internation normalized ratio
Continuous renal replacement therapy
Right bundle branch block
Intraventricular conduction delay
Advanced cardiac life support
Continuous veno-venous hemodiafiltration
Activated clotting time
Left ventricular ejection fraction
Food and drug administration
Free fatty acids.
- Firstenberg MS, Orsinelli DA: ECMO and ECHO: the evolving role of quantitative echocardiography in the management of patients requiring extracorporeal membrane oxygenation. J Am Soc Echocardiogr 2012, 25: 641–643. 10.1016/j.echo.2012.04.005View ArticlePubMed
- Platts DG, Sedgwick JF, Burstow DJ, Mullany DV, Fraser JF: The role of echocardiography in the management of patients supported by extracorporeal membrane oxygenation. J Am Soc Echocardiogr 2012, 25: 131–141. 10.1016/j.echo.2011.11.009View ArticlePubMed
- Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SAJ, Murray MJ, Peruzzi WT, Lumb PD: Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002, 30: 119–141. 10.1097/00003246-200201000-00020View ArticlePubMed
- Nasraway SAJ, Jacobi J, Murray MJ, Lumb PD: Sedation, analgesia, and neuromuscular blockade of the critically ill adult: Revised clinical practice guidelines for 2002. Crit Care Med 2002, 30: 117–118. 10.1097/00003246-200201000-00019View ArticlePubMed
- Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013, 41: 263–306.View ArticlePubMed
- Lowenstein DH: The management of refractory status epilepticus: an update. Epilepsia 2006, 47: 35–40. 10.1111/j.1528-1167.2006.00658.xView ArticlePubMed
- Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, Holtkamp M: EFNS guideline on the management of status epilepticus. Eur J Neurol 2006, 13: 445–450. 10.1111/j.1468-1331.2006.01397.xView ArticlePubMed
- Rossetti AO, Reichhart MD, Schaller M-D, Despland P-A, Bogousslavsky J: Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004, 45: 757–763. 10.1111/j.0013-9580.2004.01904.xView ArticlePubMed
- Ito H, Watanabe Y, Isshiki A, Uchino H: Neuroprotective properties of propofol and midazolam, but not pentobarbital, on neuronal damage induced by forebrain ischemia, based on the GABAA receptors. Acta Anaesthesiol Scand 1999, 43: 153–162. 10.1034/j.1399-6576.1999.430206.xView ArticlePubMed
- Biebuyck JF, Smith I, White PF, Nathanson M, Gouldson R: Propofol: an update on its clinical use. Anesthesiology 1994, 81: 1005–1043. 10.1097/00000542-199410000-00028View Article
- Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ, Waldmann CS, Verghese C: Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992, 305: 613–616. 10.1136/bmj.305.6854.613PubMed CentralView ArticlePubMed
- Bray RJ: Propofol infusion syndrome in children. Pediatr Anesth 1998, 8: 491–499. 10.1046/j.1460-9592.1998.00282.xView Article
- Hanna JP, Ramundo ML: Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998, 50: 301–303. 10.1212/WNL.50.1.301View ArticlePubMed
- Cremer OL, Moons KGM, Bouman EAC, Kruijswijk JE, De Smet AMGA, Kalkman CJ: Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001, 357: 117–118. 10.1016/S0140-6736(00)03547-9View ArticlePubMed
- Kang T: Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002, 36: 1453–1456.View ArticlePubMed
- Eriksen J, Povey HMR: A case of suspected non-neurosurgical adult fatal propofol infusion syndrome. Acta Anaesthesiol Scand 2006, 50: 117–119. 10.1111/j.1399-6576.2006.00904.xView ArticlePubMed
- Corbett SM, Montoya ID, Moore FA: Propofol-related infusion syndrome in intensive care patients. Pharmacotherapy J Hum Pharmacol Drug Ther 2008, 28: 250–258. 10.1592/phco.28.2.250View Article
- Tseng Y-T, Hao W-R, Liu J-C, Hsieh M-H: Propofol infusion syndrome leads to severe right heart injury and lethal arrhythmias. J Exp Clin Med 2010, 2: 192–195. 10.1016/S1878-3317(10)60030-7View Article
- Vernooy K, Delhaas T, Cremer OL, Di Diego JM, Oliva A, Timmermans C, Volders PG, Prinzen FW, Crijns HJGM, Antzelevitch C, Kalkman CJ, Rodriguez L-M, Brugada R: Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm 2006, 3: 131–137. 10.1016/j.hrthm.2005.11.005PubMed CentralView ArticlePubMed
- Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003, 29: 1417–1425. 10.1007/s00134-003-1905-xView ArticlePubMed
- Liolios A, Guérit J-M, Scholtes J-L, Raftopoulos C, Hantson P: Propofol infusion syndrome associated with short-term large-dose infusion during surgical anesthesia in an adult. Anesth Analg 2005, 100: 1804–1806. 10.1213/01.ANE.0000153017.93666.BFView ArticlePubMed
- Merz TM, Regli B, Rothen H-U, Felleiter P: Propofol infusion syndrome—a fatal case at a low infusion rate. Anesth Analg 2006, 103: 1050. 10.1213/01.ane.0000239080.82501.c7View ArticlePubMed
- Casserly B, O’Mahony E, Timm EG, Haqqie S, Eisele G, Urizar R: Propofol infusion syndrome: an unusual cause of renal failure. Am J Kidney Dis 2004, 44: e98-e101. 10.1053/j.ajkd.2004.08.036View ArticlePubMed
- Wolf A, Weir P, Segar P, Stone J, Shield J: Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001, 357: 606–607. 10.1016/S0140-6736(00)04064-2View ArticlePubMed
- Schenkman KA, Yan S: Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med 2000, 28: 172–177. 10.1097/00003246-200001000-00028View ArticlePubMed
- Bhatnagar D, Carey P, Pollard A: Focal myositis and elevated creatine kinase levels in a patient with phaeochromocytoma. Postgrad Med J 1986, 62: 197–198. 10.1136/pgmj.62.725.197PubMed CentralView ArticlePubMed
- Abraham J, Mudd JO, Kapur N, Klein K, Champion HC, Wittstein IS: Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol 2009, 53: 1320–1325. 10.1016/j.jacc.2009.02.020View ArticlePubMed
- Bybee KA, Prasad A: Stress-related cardiomyopathy syndromes. Circulation 2008, 118: 397–409. 10.1161/CIRCULATIONAHA.106.677625View ArticlePubMed
- Lee V, Oh J, Mulvagh S, Wijdicks E: Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2006, 5: 243–249. 10.1385/NCC:5:3:243View ArticlePubMed
- Withington DE, Decell MK, Ayed TA: A case of propofol toxicity: further evidence for a causal mechanism. Pediatr Anesth 2004, 14: 505–508. 10.1111/j.1460-9592.2004.01299.xView Article
- Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B: Review of ECMO (extracorporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008,17(4):S41-S47.View ArticlePubMed
- Pham T, Combes A, Rozé H, Chevret S, Mercat A, Roch A, Mourvillier B, Ara-Somohano C, Bastien O, Zogheib E, Clavel M, Constan A, Marie Richard J-C, Brun-Buisson C, Brochard L: Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)–induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med 2013, 187: 276–285. 10.1164/rccm.201205-0815OCView ArticlePubMed
- Abrahams JMRG, Acker MA, Sinson GP: Propofol. J Neurosurg 2002, 96: 1160–1161.PubMed
- Culp KE, Augoustides JG, Ochroch AE, Milas BL: Clinical management of cardiogenic shock associated with prolonged propofol infusion. Anesth Analg 2004, 99: 221–226. 10.1213/01.ANE.0000117285.12600.C1View ArticlePubMed
- Guitton C, Gabillet L, Latour P, Rigal J-C, Boutoille D, Al Habash O, Derkinderen P, Bretonniere C, Villers D: Propofol infusion syndrome during refractory status epilepticus in a young adult: successful ECMO resuscitation. Neurocrit Care 2011, 15: 139–145. 10.1007/s12028-010-9385-7View ArticlePubMed
- Fong JJ, Sylvia L, Ruthazer R, Schumaker G, Kcomt M, Devlin JW: Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med 2008, 36: 2281–2287. 2210.1097/CCM.2280b2013e318180c318181eb 10.1097/CCM.0b013e318180c1ebView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.